My Companies
Notification
Account
Log Out
Login
Varenyam Bio expanded its Savli facility to add biologics and biosimilar CDMO capability alongside oncology, targeting US, EU and SRA markets. Phase 1 capex doubled to ₹300 crore from ₹150 crore, with completion targeted for Q2 2028. Context: timeline extends beyond the earlier September 2027 target.
Bharat Parenterals Subsidiary Receives USFDA EIR For Vadodara Injectable Facility
Bharat Parenterals Commences US Commercial Supply Via Subsidiary Innoxel Lifesciences
Bharat Parenterals Board Approves ₹139 Crore Preferential Share Allotment